Cancer name Breast Cancer
Cancer Type BRCA
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment CD73-siRNA-loaded ChLa NPs
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature CD73
Official Symbol NT5E
Mode of action TRAN_D_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description siRNA-loaded ChLa NPs could markedly decrease the CD73 mRNA expression in 4T1 cells which was comparable with the silencing effect of JETPEI-mediated siRNA transfection. While the siRNA-loaded NPs decreasedthe expression of CD73 about 58.5 %, JETPEI-siRNA down-regulated CD73 mRNA up to 62.3 %.
PMID 26733167
Title Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles.